{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:38:04Z","timestamp":1715906284945},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"DOI":"10.7759\/cureus.60423","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:29:37Z","timestamp":1715862577000},"source":"Crossref","is-referenced-by-count":0,"title":["Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease"],"prefix":"10.7759","author":[{"given":"Ankit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya","family":"Kant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijeta","family":"Niranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.04038","article-title":"Prevalence of COPD among population above 30 years in India: a systematic review and meta-analysis","volume":"11","author":"Verma A","year":"2021","unstructured":"Verma A, Gudi N, Yadav UN, Roy MP, Mahmood A, Nagaraja R, Nayak P. Prevalence of COPD among population above 30 years in India: a systematic review and meta-analysis. J Glob Health. 2021, 11:04038. 10.7189\/jogh.11.04038","journal-title":"J Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-179","article-title":"Contribution of smoking and air pollution exposure in urban areas to social differences in respiratory health","volume":"8","author":"Schikowski T","year":"2008","unstructured":"Schikowski T, Sugiri D, Reimann V, Pesch B, Ranft U, Kr\u00e4mer U. Contribution of smoking and air pollution exposure in urban areas to social differences in respiratory health. BMC Public Health. 2008, 8:179. 10.1186\/1471-2458-8-179","journal-title":"BMC Public Health"},{"key":"ref3","article-title":"Implications of the GOLD COPD Classification and Guidelines","volume":"32","author":"Martinez CH","year":"2015","unstructured":"Martinez CH, Curtis JL. Implications of the GOLD COPD Classification and Guidelines. Fed Pract. 2015, 32:14S-8S.","journal-title":"Fed Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S330817","article-title":"Treatable traits in COPD - a proposed approach","volume":"16","author":"Cardoso J","year":"2021","unstructured":"Cardoso J, Ferreira AJ, Guimar\u00e3es M, Oliveira AS, Sim\u00e3o P, Sucena M. Treatable traits in COPD - a proposed approach. Int J Chron Obstruct Pulmon Dis. 2021, 16:3167-82. 10.2147\/COPD.S330817","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0118-2021","article-title":"The use of treatable traits to address COPD complexity and heterogeneity and to inform the care","volume":"17","author":"Duszyk K","year":"2021","unstructured":"Duszyk K, McLoughlin RF, Gibson PG, McDonald VM. The use of treatable traits to address COPD complexity and heterogeneity and to inform the care. Breathe (Sheff). 2021, 17:210118. 10.1183\/20734735.0118-2021","journal-title":"Breathe (Sheff)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report","volume":"53","author":"McDonald VM","year":"2019","unstructured":"McDonald VM, Fingleton J, Agusti A, et al.. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 2019, 53:1802058. 10.1183\/13993003.02058-2018","journal-title":"Eur Respir J"},{"key":"ref7","unstructured":"Global strategy for prevention, diagnosis and management of COPD. 2023 report. (2023). Accessed: March 6, 2024: https:\/\/goldcopd.org\/2023-gold-report-2\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20032294","article-title":"Early origins of chronic obstructive pulmonary disease: prenatal and early life risk factors","volume":"20","author":"Deolmi M","year":"2023","unstructured":"Deolmi M, Decarolis NM, Motta M, Makrinioti H, Fainardi V, Pisi G, Esposito S. Early origins of chronic obstructive pulmonary disease: prenatal and early life risk factors. Int J Environ Res Public Health. 2023, 20:2294. 10.3390\/ijerph20032294","journal-title":"Int J Environ Res Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315609251","article-title":"Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease","volume":"7","author":"George L","year":"2016","unstructured":"George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016, 7:34-51. 10.1177\/2040622315609251","journal-title":"Ther Adv Chronic Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24657-w","article-title":"Development of airflow limitation, dyspnoea, and both in the general population: the Nagahama study","volume":"12","author":"Kogo M","year":"2022","unstructured":"Kogo M, Sato S, Muro S, et al.. Development of airflow limitation, dyspnoea, and both in the general population: the Nagahama study. Sci Rep. 2022, 12:20060. 10.1038\/s41598-022-24657-w","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105938","article-title":"Goals of COPD treatment: focus on symptoms and exacerbations","volume":"166","author":"Vogelmeier CF","year":"2020","unstructured":"Vogelmeier CF, Rom\u00e1n-Rodr\u00edguez M, Singh D, Han MK, Rodr\u00edguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020, 166:105938. 10.1016\/j.rmed.2020.105938","journal-title":"Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S428391","article-title":"Can treatable traits be the approach to addressing the complexity and heterogeneity of COPD?","volume":"18","author":"Cazzola M","year":"2023","unstructured":"Cazzola M, Rogliani P, Blasi F. Can treatable traits be the approach to addressing the complexity and heterogeneity of COPD?. Int J Chron Obstruct Pulmon Dis. 2023, 18:1959-64. 10.2147\/COPD.S428391","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable traits in airway disease: from theory to practice","volume":"11","author":"Agusti A","year":"2023","unstructured":"Agusti A, Gibson PG, McDonald VM. Treatable traits in airway disease: from theory to practice. J Allergy Clin Immunol Pract. 2023, 11:713-23. 10.1016\/j.jaip.2023.01.011","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S139470","article-title":"Impact and prevention of severe exacerbations of COPD: a review of the evidence","volume":"12","author":"Halpin DM","year":"2017","unstructured":"Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017, 12:2891-908. 10.2147\/COPD.S139470","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231208630","article-title":"Stepwise management of COPD: what is next after bronchodilation?","author":"Miravitlles M","year":"2023","unstructured":"Miravitlles M, Matsunaga K, Dreher M. Stepwise management of COPD: what is next after bronchodilation?. Ther Adv Respir Dis. 2023,","journal-title":"Ther Adv Respir Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012066.pub2","article-title":"Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)","volume":"2","author":"Horita N","year":"2017","unstructured":"Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017, 2:CD012066. 10.1002\/14651858.CD012066.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S160577","article-title":"Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD","volume":"13","author":"D'Urzo AD","year":"2018","unstructured":"D'Urzo AD, Kardos P, Wiseman R. Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018, 13:1089-104. 10.2147\/COPD.S160577","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S189585","article-title":"Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population","volume":"14","author":"Vestbo J","year":"2019","unstructured":"Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population. Int J Chron Obstruct Pulmon Dis. 2019, 14:853-61. 10.2147\/COPD.S189585","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S89849","article-title":"Roflumilast: a review of its use in the treatment of COPD","volume":"11","author":"Wedzicha JA","year":"2016","unstructured":"Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016, 11:81-90. 10.2147\/COPD.S89849","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-015-0068-z","article-title":"Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer","volume":"4","author":"King PT","year":"2015","unstructured":"King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015, 4:68. 10.1186\/s40169-015-0068-z","journal-title":"Clin Transl Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.020","article-title":"Biologics and chronic obstructive pulmonary disease","volume":"141","author":"Pavord ID","year":"2018","unstructured":"Pavord ID. Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018, 141:1983-91. 10.1016\/j.jaci.2018.04.020","journal-title":"J Allergy Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113263","article-title":"Treatable traits in chronic respiratory disease: a comprehensive review","volume":"10","author":"Lee YQ","year":"2021","unstructured":"Lee YQ, Selvakumar A, See KC. Treatable traits in chronic respiratory disease: a comprehensive review. Cells. 2021, 10:3263. 10.3390\/cells10113263","journal-title":"Cells"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092181","article-title":"Eosinophilic inflammation: an appealing target for pharmacologic treatments in severe asthma","volume":"10","author":"Vatrella A","year":"2022","unstructured":"Vatrella A, Maglio A, Pelaia C, Ciampo L, Pelaia G, Vitale C. Eosinophilic inflammation: an appealing target for pharmacologic treatments in severe asthma. Biomedicines. 2022, 10:2181. 10.3390\/biomedicines10092181","journal-title":"Biomedicines"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-77","article-title":"Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study","volume":"11","author":"Singh D","year":"2010","unstructured":"Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010, 11:77. 10.1186\/1465-9921-11-77","journal-title":"Respir Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-874","article-title":"Chronic cough\u2014the limitation and advances in assessment techniques","volume":"14","author":"Zhang M","year":"2022","unstructured":"Zhang M, Sykes DL, Brindle K, Sadofsky LR, Morice AH. Chronic cough\u2014the limitation and advances in assessment techniques. J Thorac Dis. 2022, 14:5097-119. 10.21037\/jtd-22-874","journal-title":"J Thorac Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8840594","article-title":"Mucus hypersecretion in chronic obstructive pulmonary disease and its treatment","volume":"2023","author":"Shah BK","year":"2023","unstructured":"Shah BK, Singh B, Wang Y, Xie S, Wang C. Mucus hypersecretion in chronic obstructive pulmonary disease and its treatment. Mediators Inflamm. 2023, 2023:8840594. 10.1155\/2023\/8840594","journal-title":"Mediators Inflamm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.03.010","article-title":"Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD","volume":"109","author":"Rossi A","year":"2015","unstructured":"Rossi A, Aisanov Z, Avdeev S, et al.. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015, 109:785-802. 10.1016\/j.rmed.2015.03.010","journal-title":"Respir Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01269-2018","article-title":"Treatable traits in bronchiectasis","volume":"52","author":"Boaventura R","year":"2018","unstructured":"Boaventura R, Sibila O, Agusti A, Chalmers JD. Treatable traits in bronchiectasis. Eur Respir J. 2018, 52:10.1183\/13993003.01269-2018","journal-title":"Eur Respir J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/ijrc.ijrc_4_20","article-title":"An insight into bronchiectasis: causes, clinical features, and treatment practices","volume":"7","author":"Kumar S","year":"2020","unstructured":"Kumar S, Kushwaha RAS, Garg R, Devi L, Kumar A. An insight into bronchiectasis: causes, clinical features, and treatment practices. Indian J Respir Care. 2020, 7:178-82. 10.4103\/ijrc.ijrc_4_20","journal-title":"Indian J Respir Care"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1190885","article-title":"Effect of smoking on the development of chronic obstructive pulmonary disease in young individuals: a nationwide cohort study","volume":"10","author":"Chung C","year":"2023","unstructured":"Chung C, Lee KN, Han K, Shin DW, Lee SW. Effect of smoking on the development of chronic obstructive pulmonary disease in young individuals: a nationwide cohort study. Front Med (Lausanne). 2023, 10:1190885. 10.3389\/fmed.2023.1190885","journal-title":"Front Med (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132889","article-title":"Chronic obstructive pulmonary disease: epidemiology, biomarkers, and paving the way to lung cancer","volume":"10","author":"Szalontai K","year":"2021","unstructured":"Szalontai K, G\u00e9mes N, Fur\u00e1k J, et al.. Chronic obstructive pulmonary disease: epidemiology, biomarkers, and paving the way to lung cancer. J Clin Med. 2021, 10:2889. 10.3390\/jcm10132889","journal-title":"J Clin Med"},{"key":"ref32","article-title":"Adherence to disease management programs in patients with COPD","volume":"2","author":"George J","year":"2007","unstructured":"George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2007, 2:253.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238623-phenotype-to-treatable-traits-based-management-in-chronic-obstructive-pulmonary-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T12:29:46Z","timestamp":1715862586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238623-phenotype-to-treatable-traits-based-management-in-chronic-obstructive-pulmonary-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.60423","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}